Tag Line
Choose
   
   
   
   

 
Home • About Us • Business Strategy
Business Strategy
 

We are applying a "fast-follower" approach to product development in multiple areas, which allows us to strategically reduce, limit or stage development risks and costs in several ways.  In implementing this approach we focus heavily on the following:

  • Developing products in well defined disease areas to address major unmet medical needs
  • Identifying and developing best-in-class, highly differentiated products that act by well validated mechanisms of action
  • Leveraging the prior (or ongoing) clinical and/or commercial efforts and validation of others, in order to produce better, safer and/or more convenient therapeutics than our competitors (but not developing “me-too” therapeutics)

Our approach and proprietary technologies (RAGE and MultiStem®) have enabled us to identify, validate, and develop potential best-in-class therapeutic candidates across multiple disease areas targeted toward clinically meaningful, attractive commercial markets. Our technologies, particularly RAGE, have proven successful multiple times in drug development partnerships with other pharmaceutical companies, and provide us with the capability to rapidly pursue new opportunities as they arise.

Our current resources are largely being applied toward product development, with several programs, including ATHX-105 for obesity, and MultiStem in GvHD/oncology support and in myocardial infarction, in or expected to enter clinical development in the near future. We are committed to maintaining a lean operational infrastructure as we advance our product programs. We are also pursuing development programs in CNS disorders, stroke, and other clinically and commercially significant conditions.

Our long term commercial strategy is to advance products in selected areas through clinical trials and onto the market.  While we advance certain programs on our own, we also intend to explore partnering opportunities for some of our programs at various stages of development. In establishing partnerships with other companies, we will seek to maximize value for our shareholders.